BioPharma Credit PLC Dividend Declaration (9349M)
14 Mayo 2020 - 09:00AM
UK Regulatory
TIDMBPCR
RNS Number : 9349M
BioPharma Credit PLC
14 May 2020
BIOPHARMA CREDIT PLC
("BIOPHARMA CREDIT" OR THE "COMPANY")
DIVIDEND DECLARATION
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences
debt investor, is pleased to declare an interim dividend in respect
of the financial period ending 31 March 2020 of $0.0175 per
ordinary share, payable on 19 June 2020 to ordinary shareholders on
the register as at 22 May 2020. The Company has chosen to designate
the entire amount of this interim dividend as an interest
distribution. Shareholders in receipt of such a dividend will be
treated for UK tax purposes as though they have received a payment
of interest. This will result in a reduction in the corporation tax
payable by the Company.
The Company is currently paying and continues to target a 7 cent
annual dividend per ordinary share.
The default payment for dividends is in US dollars. However,
shareholders can elect to have dividends paid in sterling (GBP) and
the option to elect a sterling dividend payment for this dividend
will be available to shareholders until 22 May 2020 (the "Election
Date").
Further details together with a copy of the Dividend Currency
Election Form, which should be sent to Link Asset Services, The
Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU when
completed, will be available on the Group's website shortly at
www.bpcruk.com/investor-materials. CREST shareholders must elect
via CREST.
LEI: 213800AV55PYXAS7SY24
-Ends-
Link Company Matters Limited
Company Secretary
14 May 2020
Enquiries:
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
Biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DIVAIMBTMTBBBAM
(END) Dow Jones Newswires
May 14, 2020 10:00 ET (14:00 GMT)
Biopharma Credit (LSE:BPCR)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Biopharma Credit (LSE:BPCR)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024